Kimball Electronics Inc. 2026年季度报告

(Mark One)☒QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934For the quarterly period ended December31, 2025☐TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 KIMBALL ELECTRONICS, INC. (Exact name of registrant as specified in its charter) 35-2047713(I.R.S. Employer Identification No.) (812) 634-4000Registrant’s telephone number, including area codeNot Applicable Securities registered pursuant to Section 12(b) of the Act: Title of each ClassTrading Symbol Common Stock, no par valueKE Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the SecuritiesExchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.Yes☒No☐ Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submittedpursuant to Rule 405 of Regulation S-T (Section 232.405 of this chapter) during the preceding 12 months (or for such shorter periodthat the registrant was required to submit such files). Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smallerreporting company, or an emerging growth company.See the definitions of “large accelerated filer,” “accelerated filer,” “smallerreporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act. If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period forcomplyingwithanyneworrevisedfinancialaccountingstandardsprovidedpursuanttoSection13(a)oftheExchangeAct.☐ Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).Yes☐No☒ The number of shares outstanding of the Registrant’s common stock as of January22, 2026 was 24,214,134 shares. PART IFINANCIAL INFORMATION Item 1. Financial Statements Condensed Consolidated Balance Sheets- December 31, 2025 (Unaudited) and June 30, 20253Condensed Consolidated Statements of Income (Unaudited)- Three and Six Months Ended December 31, 2025 and 20244Condensed Consolidated Statements of Comprehensive Income (Unaudited)- Three and Six Months Ended December 31, 2025 and 20245Condensed Consolidated Statements of Cash Flows (Unaudited)- Six Months Ended December 31, 2025 and 20246Condensed Consolidated Statements of Share Owners’ Equity (Unaudited)- Three and Six Months Ended December 31, 2025 and 20247Notes to Condensed Consolidated Financial Statements (Unaudited)8 Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations23Item 3. Quantitative and Qualitative Disclosures About Market Risk31Item 4. Controls and Procedures31 PART IIOTHER INFORMATION Item 1. Legal Proceedings32Item 1A. Risk Factors32Item 2. Unregistered Sales of Equity Securities and Use of Proceeds32Item 5. Other Information32Item 6. Exhibits33 34 PART I. FINANCIAL INFORMATIONItem 1. Financial StatementsKIMBALL ELECTRONICS, INC.CONDENSED CONSOLIDATED BALANCE SHEETS(Amounts in Thousands, Except for Share Data) ASSETS Current Assets: Cash and cash equivalents$77,853$88,781Receivables, net of allowances of $461 and $102, respectively213,994222,623Contract assets79,52171,812Inventories281,699273,500 KIMBALL ELECTRONICS, INC.NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS Note 1. Business Description and Summary of Significant Accounting Policies Business Description: Kimball Electronics, Inc. (also referred to herein as “Kimball Electronics,” the “Company,” “we,” “us,” or “our”) is a global,multifaceted manufacturing solutions provider. We provide electronics manufacturing services (“EMS”), including engineering andsupply chain support, to customers in the automotive, medical, and industrial end markets. We further produce higher level and finalassemblies and offer contract manufacturing organization (“CMO”) solutions which include the production of medical disposables anddrug delivery devices, from precision molded plastics and cold chain management to drug integration. Our design and manufacturingexpertise coupled with robust processes and procedures help us ensure that we deliver the highest levels of quality, reliability, and Basis of Presentation: The Condensed Consolidated Financial Statements presented herein reflect the consolidated financial position as of December31,2025 and June30, 2025, results of operations for the three and six months ended December31, 2025 and 2024, cash flows for the sixmonths ended December31, 2025 and 2024, and share owners’ equity for the three and six months ended December31, 2025 and2024. The financial data presented herein is unaudited and should be read in conjunction with the annual Consolidated FinancialStatements as of and for the